GENFIT (GNFT) Competitors $3.97 +0.18 (+4.75%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNFT vs. NUVB, QURE, PHAR, CRON, SION, ANAB, GHRS, DNA, NAGE, and TNGXShould you be buying GENFIT stock or one of its competitors? The main competitors of GENFIT include Nuvation Bio (NUVB), uniQure (QURE), Pharming Group (PHAR), Cronos Group (CRON), Sionna Therapeutics (SION), AnaptysBio (ANAB), GH Research (GHRS), Ginkgo Bioworks (DNA), Niagen Bioscience (NAGE), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry. GENFIT vs. Its Competitors Nuvation Bio uniQure Pharming Group Cronos Group Sionna Therapeutics AnaptysBio GH Research Ginkgo Bioworks Niagen Bioscience Tango Therapeutics Nuvation Bio (NYSE:NUVB) and GENFIT (NASDAQ:GNFT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation. Do analysts prefer NUVB or GNFT? Nuvation Bio currently has a consensus price target of $7.33, indicating a potential upside of 182.05%. GENFIT has a consensus price target of $13.00, indicating a potential upside of 227.46%. Given GENFIT's higher possible upside, analysts clearly believe GENFIT is more favorable than Nuvation Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17GENFIT 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor NUVB or GNFT? In the previous week, Nuvation Bio had 11 more articles in the media than GENFIT. MarketBeat recorded 12 mentions for Nuvation Bio and 1 mentions for GENFIT. GENFIT's average media sentiment score of 1.87 beat Nuvation Bio's score of 0.29 indicating that GENFIT is being referred to more favorably in the news media. Company Overall Sentiment Nuvation Bio Neutral GENFIT Very Positive Is NUVB or GNFT more profitable? GENFIT has a net margin of 0.00% compared to Nuvation Bio's net margin of -1,413.43%. GENFIT's return on equity of 0.00% beat Nuvation Bio's return on equity.Company Net Margins Return on Equity Return on Assets Nuvation Bio-1,413.43% -46.14% -36.04% GENFIT N/A N/A N/A Do insiders & institutionals believe in NUVB or GNFT? 61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 2.2% of GENFIT shares are owned by institutional investors. 29.9% of Nuvation Bio shares are owned by insiders. Comparatively, 4.2% of GENFIT shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk and volatility, NUVB or GNFT? Nuvation Bio has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Comparatively, GENFIT has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Which has stronger earnings and valuation, NUVB or GNFT? GENFIT has higher revenue and earnings than Nuvation Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvation Bio$7.87M112.41-$567.94M-$0.63-4.13GENFIT$67.00M2.96$1.63MN/AN/A SummaryNuvation Bio beats GENFIT on 8 of the 15 factors compared between the two stocks. Get GENFIT News Delivered to You Automatically Sign up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNFT vs. The Competition Export to ExcelMetricGENFITMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$198.51M$3.09B$5.64B$9.82BDividend YieldN/A2.29%4.64%4.14%P/E RatioN/A20.6830.1125.77Price / Sales2.96327.50452.24168.51Price / Cash53.3340.7837.7258.50Price / Book2.657.718.476.07Net Income$1.63M-$54.65M$3.26B$265.11M7 Day Performance7.15%3.97%3.55%2.90%1 Month Performance8.77%11.49%5.96%4.00%1 Year Performance-1.24%13.04%42.69%26.92% GENFIT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNFTGENFIT1.911 of 5 stars$3.97+4.7%$13.00+227.5%-6.2%$198.51M$67.00M0.00120Positive NewsGap UpNUVBNuvation Bio1.9896 of 5 stars$2.31+3.6%$7.17+210.2%-17.7%$758.79M$7.87M-0.9860Earnings ReportQUREuniQure3.0158 of 5 stars$13.77+0.6%$36.55+165.4%+98.1%$751.40M$27.12M-3.51500PHARPharming Group2.8015 of 5 stars$12.25+11.8%$30.00+144.9%+48.3%$750.92M$297.20M-94.23280Gap DownHigh Trading VolumeCRONCronos Group1.4287 of 5 stars$2.02+3.6%N/A+18.5%$748.42M$117.61M15.54450News CoverageEarnings ReportAnalyst RevisionSIONSionna TherapeuticsN/A$17.12+1.2%$38.50+124.9%N/A$746.59MN/A0.0035News CoverageEarnings ReportANABAnaptysBio3.1062 of 5 stars$24.23-1.9%$47.13+94.5%-40.4%$725.40M$91.28M-5.00100News CoveragePositive NewsEarnings ReportAnalyst ForecastAnalyst RevisionGHRSGH Research2.2518 of 5 stars$13.44-2.2%$32.00+138.1%+23.6%$714.87MN/A-17.0110Positive NewsEarnings ReportAnalyst RevisionDNAGinkgo Bioworks0.9104 of 5 stars$13.62+11.7%$8.50-37.6%N/A$713.50M$227.04M-1.49640News CoverageEarnings ReportNAGENiagen Bioscience1.321 of 5 stars$9.64+6.6%$13.22+37.1%N/A$712.08M$99.60M56.71120News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionTNGXTango Therapeutics2.0108 of 5 stars$6.59+0.9%$10.50+59.3%-20.5%$707.81M$40.99M-5.4090Positive NewsAnalyst Revision Related Companies and Tools Related Companies Nuvation Bio Alternatives uniQure Alternatives Pharming Group Alternatives Cronos Group Alternatives Sionna Therapeutics Alternatives AnaptysBio Alternatives GH Research Alternatives Ginkgo Bioworks Alternatives Niagen Bioscience Alternatives Tango Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNFT) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GENFIT S.A. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share GENFIT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access